Pneumococcal vaccine GSK1024850A — Competitive Intelligence Brief

Pneumococcal vaccine GSK1024850A (Pneumococcal vaccine GSK1024850A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pneumococcal conjugate vaccine. Area: Immunology.

phase 3 Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides Immunology Biologic

Target snapshot

Pneumococcal vaccine GSK1024850A (Pneumococcal vaccine GSK1024850A) — GlaxoSmithKline. This pneumococcal conjugate vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae bacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pneumococcal vaccine GSK1024850A TARGET	Pneumococcal vaccine GSK1024850A	GlaxoSmithKline	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
PPV23 alone	PPV23 alone	Korea University Guro Hospital	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
ProDiax-23 (PPSV23)	ProDiax-23 (PPSV23)	Korea University Guro Hospital	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
Control 23-valent PPV	Control 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
pneumococcal conjugate 13 valent vaccine	pneumococcal conjugate 13 valent vaccine	University of Siena	marketed	Conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (13 serotypes)
Influenza vaccination with PCV13	Influenza vaccination with PCV13	Korea University Guro Hospital	marketed	Conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Pneumococcal conjugate vaccine class)

1. GlaxoSmithKline · 12 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Korea University Guro Hospital · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. Papua New Guinea Institute of Medical Research · 1 drug in this class
6. Pfizer Inc. · 1 drug in this class
7. Sanofi · 1 drug in this class
8. University of Minnesota · 1 drug in this class
9. University of Oxford · 1 drug in this class
10. Vabiotech · 1 drug in this class